Researchers at the Medical University of Vienna and the Medical University of Innsbruck discovered that SARS-CoV-2 hijacks ...

The Complement group, headed by Prof. Seppo Meri, has for long had an interest in sorting out how and why the complement system contributes to disease pathogenesis, how the system is controlled and ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...

Inflarx N.V. ( (IFRX) ) has released its Q3 earnings. Here is a breakdown of the information Inflarx N.V. presented to its investors. InflaRx N.V. is a biopharmaceutical company focused on developing ...